Stephen W. Behrman MD
The University of Tennessee Health Science Center
Stephen W. Behrman, MD, is Professor of Surgery at The University of Tennessee Health Science Center. He is Chair of the Department of Surgery at Baptist Memorial Hospital - Memphis and is Chair of the Surgical Residency Program at that institution. His primary area of expertise is benign and malignant disorders of the pancreas.
Dr. Behrman earned his medical degree from Boston University. He completed his surgical residency at The University of Tennessee Health Science Center (UTHSC), and his gastrointestinal surgery fellowship at The Ohio State University. He served as an officer in the United States Naval Reserve from 1998-2005.
Dr. Behrman established the Herb Kosten Pancreatic Research Endowment Fund in Memphis, TN that includes funding for research, an annual symposium and a local support group for patients and families. His clinical research focuses on improving outcomes for those having pancreatic surgery and he has been involved in multi-institutional collaboratives on these endeavors. His translational research focuses on the utilization mRNA and nanotechnology in cancer therapeutics for the treatment of pancreas cancer.
Dr. Behrman is a long-term member of the NCCN Pancreatic Adenocarcinoma Panel and chairs the committee that is developing guidelines relative to carcinoma of the ampulla of Vater.
Dr. Behrman earned his medical degree from Boston University. He completed his surgical residency at The University of Tennessee Health Science Center (UTHSC), and his gastrointestinal surgery fellowship at The Ohio State University. He served as an officer in the United States Naval Reserve from 1998-2005.
Dr. Behrman established the Herb Kosten Pancreatic Research Endowment Fund in Memphis, TN that includes funding for research, an annual symposium and a local support group for patients and families. His clinical research focuses on improving outcomes for those having pancreatic surgery and he has been involved in multi-institutional collaboratives on these endeavors. His translational research focuses on the utilization mRNA and nanotechnology in cancer therapeutics for the treatment of pancreas cancer.
Dr. Behrman is a long-term member of the NCCN Pancreatic Adenocarcinoma Panel and chairs the committee that is developing guidelines relative to carcinoma of the ampulla of Vater.